Using artificial intelligence to improve parathyroid adenoma detection
Contribution to Disease Diagnosis and Prognosis Based on the Fusion of Expert Knowledge, Nuclear Medicine Imaging and Artificial Intelligence (AI) Tools
This study is testing whether using artificial intelligence can help doctors find parathyroid adenomas more accurately in patients who have had specific imaging tests.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Besancon Academic / other |
| Locations | 1 site (Besançon) |
| Trial ID | NCT05963841 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop artificial intelligence algorithms to enhance the detection of parathyroid adenomas in patients who have undergone dual-isotope parathyroid scintigraphy. The study will utilize existing imaging data from standard diagnostic procedures to create a program that automatically subtracts planar and tomographic images, thereby improving the localization of adenomas. The research will also evaluate the concordance between diagnoses made using traditional methods and the new AI-assisted approach. The goal is to streamline the diagnostic process and improve accuracy in identifying parathyroid conditions.
Who should consider this trial
Good fit: Ideal candidates are men and women over 18 years old who have undergone dual-isotope parathyroid scintigraphy as per the standard protocol.
Not a fit: Patients who refuse to allow their data to be used for research purposes or who did not follow the standard acquisition protocol will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and efficient diagnosis of hyperparathyroidism, potentially improving patient outcomes.
How similar studies have performed: While there are existing software solutions for parathyroid imaging, this study's focus on AI-driven automatic image processing represents a novel approach that has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women over 18 years of age who underwent dual-isotope parathyroid scintigraphy. * No refusal to use data for research purposes * Retrospective data (after 13/04/2022: Date of posting of patient information in the department) and prospective data Exclusion Criteria: * Patient refusal to use data for research purposes * Patients who did not benefit from the standard acquisition protocol (123I injection followed by 99mTc 3 hours after LEHR, PINHOLE and SPECT/CT acquisitions)
Where this trial is running
Besançon
- CHU Besancon — Besançon, France (Recruiting)
Study contacts
- Study coordinator: Laurent COMAS
- Email: lcomas@chu-besancon.fr
- Phone: 0381218477
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.